A KRAS A146 mutation assay was included on the MALDI-TOF panel and no mutations were detected, consistent with previous reports suggesting this particular mutation, although relevant in colorectal cancer, is not important in NSCLC [12], [14]. Here, KRAS is linked to colorectal cancer.